Vaso Corporation Announces Termination of Business Combination Agreement with Achari Ventures Holdings Corp. I
Vaso (OTCQX: VASO) has announced the termination of its Business Combination Agreement with Achari Ventures Holdings Corp. I. The company, based in Plainview, N.Y., made this decision on September 18, 2024. Vaso stated that it will continue to pursue opportunities to enhance stockholder value through various means, including:
- Internal growth
- New partnerships
- Strategic investments
The company's focus will remain on medical and IT service companies as it seeks to expand its business and create value for shareholders.
Vaso (OTCQX: VASO) ha annunciato la risoluzione del suo Accordo di Combinazione Aziendale con Achari Ventures Holdings Corp. I. La società, con sede a Plainview, N.Y., ha preso questa decisione il 18 settembre 2024. Vaso ha dichiarato che continuerà a cercare opportunità per migliorare il valore per gli azionisti attraverso vari mezzi, tra cui:
- Crescita interna
- Nuove partnership
- Investimenti strategici
Il focus dell'azienda rimarrà sulle aziende di servizi medici e IT mentre cerca di espandere la propria attività e creare valore per gli azionisti.
Vaso (OTCQX: VASO) ha anunciado la terminación de su Acuerdo de Combinación Empresarial con Achari Ventures Holdings Corp. I. La empresa, con sede en Plainview, N.Y., tomó esta decisión el 18 de septiembre de 2024. Vaso declaró que continuará buscando oportunidades para aumentar el valor para los accionistas a través de varios medios, incluyendo:
- Crecimiento interno
- Nuevas asociaciones
- Inversiones estratégicas
El enfoque de la empresa seguirá siendo en compañías de servicios médicos e informáticos mientras busca expandir su negocio y crear valor para los accionistas.
Vaso (OTCQX: VASO)는 Achari Ventures Holdings Corp. I와의 사업 조합 계약을 종료한다고 발표했습니다. 뉴욕주 플레인뷰에 본사를 둔 이 회사는 2024년 9월 18일에 이 결정을 내렸습니다. Vaso는 다음을 포함하여 주주 가치를 높이기 위한 다양한 방법을 계속 모색할 것이라고 밝혔습니다:
- 내부 성장
- 새로운 파트너십
- 전략적 투자
회사의 초점은 의료 및 IT 서비스 회사에 계속 유지되며, 사업을 확장하고 주주를 위한 가치를 창출하는 것을 목표로 하고 있습니다.
Vaso (OTCQX: VASO) a annoncé la résiliation de son Accord de Combinaison Commerciale avec Achari Ventures Holdings Corp. I. La société, basée à Plainview, N.Y., a pris cette décision le 18 septembre 2024. Vaso a déclaré qu'elle continuerait à rechercher des opportunités pour améliorer la valeur des actionnaires par divers moyens, y compris :
- Croissance interne
- Nouvelles partenariats
- Investissements stratégiques
Le focus de la société restera sur les entreprises de services médicaux et informatiques alors qu'elle cherche à étendre ses activités et à créer de la valeur pour les actionnaires.
Vaso (OTCQX: VASO) hat die Beendigung seines Geschäftskombinationsvertrags mit Achari Ventures Holdings Corp. I bekannt gegeben. Das Unternehmen mit Sitz in Plainview, N.Y., hat diese Entscheidung am 18. September 2024 getroffen. Vaso erklärte, dass es weiterhin nach Möglichkeiten suchen wird, den Wert für die Aktionäre durch verschiedene Mittel zu steigern, darunter:
- Interne Wachstumsmaßnahmen
- Neue Partnerschaften
- Strategische Investitionen
Der Fokus des Unternehmens wird weiterhin auf Unternehmen im Gesundheits- und IT-Dienstleistungsbereich liegen, während es bestrebt ist, sein Geschäft auszubauen und den Aktionären einen Mehrwert zu bieten.
- Company maintains focus on growth opportunities in medical and IT service sectors
- Vaso actively seeking new partnerships and strategic investments
- Termination of Business Combination Agreement with Achari Ventures Holdings Corp. I
PLAINVIEW, N.Y., Sept. 18, 2024 (GLOBE NEWSWIRE) -- Vaso Corporation (“Vaso”) (OTCQX: VASO) today announced that it has provided notice to Achari Ventures Holdings Corp. I (“Achari”) to terminate the Business Combination Agreement with Achari. The Company will continue to seek opportunities to increase stockholder value, including through internal growth, new partnerships, and strategic investments with a concentration on medical and IT service companies.
About Vaso Corporation
Vaso Corporation is a diversified medical technology company operating in three business segments:
- IT Segment provides network and IT services through two operating units: NetWolves Network Services, a managed network services provider with an extensive, proprietary service platform to a broad base of customers; and VHC-IT, a service provider for healthcare application solutions from various vendors as well as related services, including implementation, management and support.
- Professional Sales Service Segment provides sales service of capital medical equipment through a wholly owned subsidiary VasoHealthcare, currently serving as the exclusive sales representative of GE HealthCare diagnostic imaging and ultrasound products and services in certain market segments in the USA.
- Equipment Segment manages and coordinates the design, manufacture and sales of proprietary medical equipment and software, as well as operates the Company's overseas assets including China-based subsidiaries.
Additional information is available on the Company's website at www.vasocorporation.com.
Forward Looking Statements
Except for any historical information contained in this release, the matters discussed are forward-looking statements that involve risks and uncertainties. When used in this report, words such as “anticipates”, “believes”, “could”, “estimates”, “expects”, “may”, “optimistic”, “plans”, “potential”, “looking forward”, and “intends” and similar expressions, as they relate to the Company or its management, identify forward-looking statements. Such forward-looking statements are based on the beliefs of the Company’s management, as well as assumptions made by and information currently available to the Company’s management. Among the factors that could cause actual results to differ materially are the following: the effect of business and economic conditions, including the possibility of a downturn in the US economy and the continued impact of the COVID-19 pandemic; the effect of the dramatic changes taking place in IT and healthcare; continuation of the GEHC agreement; the impact of competitive technology and products and their pricing; medical insurance reimbursement policies; manufacturing or supplier problems; unforeseen difficulties and delays in product development programs; the actions of regulatory authorities and third-party payers in the United States and overseas; and the risk factors reported from time to time in the Company’s SEC reports. The Company undertakes no obligation to update forward-looking statements as a result of future events or developments.
Investor Contact:
Michael J. Beecher
Investor Relations
Phone: 516-997-4600
Email: mbeecher@vasocorporation.com
FAQ
Why did Vaso (VASO) terminate its Business Combination Agreement with Achari Ventures Holdings Corp. I?
What are Vaso 's (VASO) plans following the termination of the agreement?
When did Vaso (VASO) announce the termination of its agreement with Achari Ventures Holdings Corp. I?
What is Vaso 's (VASO) stock exchange and ticker symbol?
